SCHEMBL2260716

SCHEMBL2260716

Cc1cc(C#N)cc(Cl)c1Oc1nc(NC2CCN(c3cccc(N)c3)CC2)ncc1Br

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 5/20 0.45
CYP2C9 P11712 2/20 0.40
ADORA1 P30542 2/20 0.38
ABCC3 O15438 1/20 0.38
ESR1 P03372 1/20 0.38
CYP1A2 P05177 1/20 0.38
PGR P06401 1/20 0.38
CHRM2 P08172 1/20 0.38
ABCB1 P08183 1/20 0.38
CYP3A4 P08684 1/20 0.38
ADRA2A P08913 1/20 0.38
CYP2D6 P10635 1/20 0.38
CHRM1 P11229 1/20 0.38
DRD1 P21728 1/20 0.38
PTGS1 P23219 1/20 0.38
SLC6A2 P23975 1/20 0.38
CYP2C19 P33261 1/20 0.38
ABCC1 P33527 1/20 0.38
OPRM1 P35372 1/20 0.38
ABCC2 Q92887 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2264155 0.90 KCNH2 (0.53) KCNH2CYP2C9CYP2C19CCNKCDK12
SCHEMBL2261644 0.89 KCNH2 (0.43) KCNH2CYP2C9CYP3A4CYP2D6CYP2C19
SCHEMBL2262338 0.88 KCNH2 (0.47) KCNH2CYP2C9ADORA1ABCC3ESR1
SCHEMBL2259839 0.87 KCNH2 (0.47) KCNH2CYP2C9ADORA1PSEN1PSEN2
SCHEMBL2262939 0.86 KCNH2 (0.48) KCNH2CYP2C9ADORA1ABCC3ESR1
SCHEMBL2263186 0.85 KCNH2 (0.56) KCNH2CYP2C9ADORA1ABCC3ESR1
SCHEMBL2262093 0.85 KCNH2 (0.51) KCNH2CYP2C9ADORA1ABCC3ESR1
SCHEMBL2264021 0.84 KCNH2 (0.50) KCNH2CYP2C9ADORA1ABCC3ESR1
SCHEMBL2263668 0.83 KCNH2 (0.46) KCNH2CYP2C9ADORA1ABCC3ESR1
SCHEMBL2262209 0.83 KCNH2 (0.48) KCNH2CYP2C9ADORA1ABCC3ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2089384-B1 2-(PIPERIDIN-4-YL)-4-PHENOXY-OR PHENYLAMINO-PYRIMIDINE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS HOFFMANN LA ROCHE (CH) 2015-08-05 EP claimed
US-7998969-B2 enzyme inhibitors such as 4-[2-(1-Benzyl-piperidin-4-ylamino)-pyrimidin-4-yloxy]-3,5-dimethyl-benzonitrile, used in combination with other viricides, for preventing and treatment of viral infections such as HIV, AIDS and AIDS related diseases ROCHE PALO ALTO LLC (US) 2011-08-16 US claimed
US-20080146595-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2008-06-19 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146595-A1 Non-nucleoside reverse transcriptase inhibitors NQO2, SAMHD1, POLR2A KCNH2 4033/4885CYP2C9 1382/4885ADORA1 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.